This content is in French.
Dual targeting of HER2 and VEGFR in ovarian cancer
1 mars 2024
Ovarian cancer is a common cancer of the female reproductive system, for which effective targeted therapies remain insufficient. In this study, researchers used clinical models of ovarian cancer to assess…
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Weisong Li et al. Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer. J Exp Clin Cancer Res. 2024 Feb 26;43(1):56.
View the source
